Quidel

Quidel EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Quidel (QDEL) as of Nov 4, 2026 is -1.79. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -0.84 — a change of 111.34% (lower).

EV/EBIT

-1.79

YoY

111.34%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Quidel is 2025 -1.79 . EV/EBIT (Enterprise Value to EBIT) of Quidel was 2024 -0.84 . It decreases by 111.34% lower compared to the previous year.

The Quidel EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2019
17.70 USD
Jan 1, 2020
1.55 USD
Jan 1, 2021
1.81 USD
Jan 1, 2022
1.95 USD
Jan 1, 2023
11.80 USD
Jan 1, 2024
-0.84 USD
Jan 1, 2025
-1.79 USD
Jan 1, 2026 (e)
3.81 USD
The Quidel EV/EBIT history
YEAREV/EBITYoY
est3.81-313.39%
-1.79+111.34%
-0.84-107.16%
11.80+506.54%
1.95+7.38%
1.81+17.03%
1.55-91.26%
17.70+3.47%
17.11-90.04%
171.82-146.47%
-369.73-161.68%
599.43-436.30%
-178.24-166.37%
268.57+269.68%
72.65+99.81%
36.36-236.49%
-26.64-441.98%
7.79-46.57%
14.58-54.09%
31.76-0.90%
32.05—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quidel Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Quidel's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Quidel's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Quidel's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Quidel grows earnings faster than its peers.

Quidel Stock analysis

What does Quidel do? Quidel Corporation is a US-based company specializing in the production of rapid tests for medical diagnostics. It was founded in 1979 and is headquartered in San Diego, California. Since 1991, it has been listed on the NASDAQ stock exchange. Quidel initially started as Diagnostic Reagents Laboratory (DRL) and focused on manufacturing diagnostic products for the veterinary sector. In 1990, it was renamed Quidel Corporation and expanded its operations into human diagnostics. The company's business model revolves around the development and production of immunological rapid tests that can quickly and easily diagnose infectious diseases and other health problems. Quidel focuses on creating high-quality, accurate, and cost-effective test procedures that can be used by healthcare professionals or even laypersons at home. One of Quidel's core competencies is bringing to market rapid tests that are easy to perform and provide immediate results without the need to send samples to a laboratory. The company offers a wide range of rapid tests for diagnosing various diseases. These include tests for infectious diseases such as influenza, streptococcus, Lyme disease, and chlamydia, as well as tests for pregnancy, drug abuse, and cardiovascular diseases. The tests are available as single tests or panel tests that can diagnose multiple diseases simultaneously. Quidel operates in four business segments: Molecular Diagnostics, Point-of-Care Diagnostics, Immunoassays, and Specialized Diagnostic Solutions. The Molecular Diagnostics segment focuses on developing molecular diagnostic tests and instruments for laboratory use. The Point-of-Care Diagnostics segment develops and produces rapid tests for use in medical practices and hospitals. The Immunoassays segment specializes in reagent-based tests for the quantitative analysis of biomolecules. The Specialized Diagnostic Solutions segment includes specialized diagnostic products, such as test systems for monitoring antibiotic therapies. In conclusion, Quidel Corporation specializes in the development and production of rapid tests for medical diagnostics. The company offers a wide range of high-quality, accurate, and cost-effective test procedures for diagnosing infectious diseases, pregnancy, drug abuse, and cardiovascular diseases. Quidel has gained a significant market share in the diagnostics field through its rapid tests and diverse range of test panels for various conditions, and it is known for its innovative products. Quidel is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Quidel stock

EV/EBIT (Enterprise Value to EBIT) of Quidel is -1.79 in 2025.

EV/EBIT (Enterprise Value to EBIT) of Quidel changed from -0.84 to -1.79, representing a 111.34% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Quidel since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Quidel with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Quidel

All Key Metrics — Quidel